Open Access

So far clinical human immunodeficiency virus (HIV) therapy is limited to non-curative treatments. However, as recently shown, alternative approaches such as HIV gene therapy have the potential to functionally cure the disease (e.g. the hematopoietic stem cell (HSC)-transplantation with a CCR5Δ32 homozygous transplant) (1). In contrast to the highly personalized medical treatment applied in the ‘Berlin case’, more broadly applicable approaches are currently under intensive investigation. One example is the adeno-associated-virus (AAV)-mediated delivery of in vivo secreted antiviral entry inhibitors (iSAVE), the concept of which is based on the direct in vivo administration of a broadly applicable highly potent antiviral gene (here: a C46-derived entry inhibitory peptide interfering with HIV-1 membrane fusion). The AAV-based gene delivery is believed to overcome several limitations of gene therapeutic treatments based on ex vivo lentiviral trials in the past. It is (i) targeting differentiated HIV target cells (i.e. liver and differentiated lymphatic cells) reducing the risk of genotoxicity compared to stem cell-based trials, (ii) overcoming the limitation of a low number of genetically modifiable cells as in lentivirally based ex vivo transduction strategies (i.e. limited modifiable cell number due to culture conditions and lower vector titers) and (iii) using the safe AAV vector system, which has not been associated with major genotoxicity in men. (iv) Most importantly, the concept of secretable entry inhibitors does not require transduction of large amounts of cells due to the protective bystander effect. Thus, iSAVE might be a treatment principle for HIV infection that might be able to cure patients irrespective of their viral isolates or adherence. Accordingly, the iSAVE concept could aim at two different sites in the patient for the production of antiviral transgenes, either the systemic production via suitable producer cells (e.g. hepatocytes) or the local production in the lymphatic system. In a first approach, we are able to efficiently target hepatocytes using the natural AAV serotype 8 to express high plasma levels of secretable antiviral entry inhibitors in order to systemically suppress viral replication. In this setting we could show that iSAVE peptides are highly expressed in hepatocytes. However, plasma levels of iSAVE were insufficient when using a secretable peptide as sole antiviral transgene. As a second treatment strategy, the iSAVE project aimed to deliver antiviral genes directly to the site of viral replication, the lymphatic system. Here, (i) a panel of naturally occurring AAV serotypes as well as (ii) AAV retargeting approaches were employed to design a highly efficient and selective AAV vector variant for gene delivery into the lymphatic system after intravenous vector administration. In detail, (i) screening of the natural occurring serotypes revealed that the AAV serotype 1 (AAV-1) was best in targeting splenic tissue in two humanized mouse models, however at a very low level. After systemic AAV-1 vector administration neither transduction of human lymphocytes did occur nor was iSAVE expressed in the lymphatic system in a humanized mouse model. (ii) In a second approach, we modified the well-characterized AAV-2 serotype in a tropism-defining region of its capsid gene by insertion of human peripheral blood lymphocytes (hPBL)-tropic peptide ligands. These in turn were selected by M13 in vivo phage display and by in vivo AAV peptide display. Selected variants were cloned and tested for hPBL transduction in vitro. Although the selected variants did not show increased expression efficacies compared to AAV-2 WT, it still might be possible that the selected variant are more specific for hPBLs as these conditions have not been tested. As these selection processes required a humanized mouse model that comprises a functional lymphatic system, we established the previously described Trimera mouse model in our lab (2). We found that this mouse model could be further improved to allow engraftment of a lower number of gene-modified (gm) human T cells as in the classical Trimera model. These modified Trimera mice (mT3 mice) were conditioned by inclusion of cyclophosphamide (CTX) to the irradiation-conditioning scheme of the classical Trimera model. Comparison of mT3 mice with established NSG and DKO mice in an adoptive gm T cell transplantation setting revealed that NSG mice were the most robust model providing high reproducibility in human T cell engraftment. MT3 mice allowed a substantial, yet more variable engraftment of gm T cells. Besides comparing engraftment kinetics, the graft quality (i.e. clonality and cytokine milieu) was analyzed. Again, NSG mice showed the most balanced homeostatic repopulation three weeks after transplantation, while mT3 mice were prone to Th1-type, oligloclonal repopulation, indicating an early onset of xenograft-versus-host disease. Finally, the lymphatic infiltration was analyzed. As expected, mT3 mice provided the most intact lymphatic structures, although the normal lymphatic morphology was not restored. In conclusion, it was demonstrated in this work that AAV-mediated iSAVE gene therapy faces specific limitations depending on the respective targeting approach In the systemic approach, iSAVE peptides have to be further optimized in terms of transgene design itself, as high-level accumulation in murine plasma was not feasible for the short iSAVE precursor. In the local, lymphatic targeting approach, AAV-mediated expression faces its limits in targeting specificity but foremost expression efficacy. Thus, the AAV vector itself needs further optimization for sufficient local iSAVE expression levels. Independently from the AAV-related approaches, a novel humanized mouse model was established in this work. Despite drawbacks regarding repopulation variability and set-up complexity, the novel mT3 mouse model comprised improved secondary lymphatic structures for adoptive T cell transfer, which might be an interesting platform for studies in lymphoma or leukemia therapy.

Prion diseases, also called transmissible spongiform encephalopathies, are a group of fatal neurodegenerative conditions that affect humans and a wide variety of animals. To date there is no therapeutic or prophylactic approach against prion diseases available. The causative infectious agent is the prion, also termed PrPSc, which is a pathological conformer of a cellular protein named prion protein PrPc. Prions are thought to multiply upon conversion of PrPc to PrPSc in a self-propagating manner. Immunotherapeutic strategies directed against PrPc represent a possible approach in preventing or curing prion diseases. Accordingly, it was already shown in animal models, that passive immunization delays the onset of prion diseases. The present thesis aimed at the development of a candidate vaccine towards the active immunization against prion diseases, an immune response, which has to be accompanied by the circumvention of host tolerance to the self-antigen PrPc. The vaccine development was approached using virus-like particles (retroparticles) derived from either the murine leukemia (MLV) or the human immunodeficiency virus (HIV). The display of PrP on the surface of such particles was addressed for both the cellular and the pathogenic form of PrP. The display of PrPc was achieved by either fusion to the transmembrane domain of the platelet derived growth factor receptor (PDGFR) or to the N-terminal part of the viral envelope protein (Env). In both cases, the corresponding PrPD- and PrPE-retroparticles were successfully produced and analyzed via immune fluorescence, Western Blot analysis, immunogold electron microscopy as well as by ELISA methods. Both, PrPD- and PrPE-retroparticles showed effective incorporation of N-terminally truncated forms of PrPc but not for the complete protein. PrPc at this revealed the typical glycosylation pattern, which was specifically removed by a glycosidase enzyme. Upon display of PrPc on retroparticles the protein remained detectable by PrP-specific antibodies under native conditions. Electron microscopy analysis of PrPc-variants revealed no alteration of the characteristic retroviral morphology of the generated particles. MLV-derived PrPD-retroparticles were successfully used in immunization studies. Contrary to approaches using bacterially expressed PrPc, the immunization of mice resulted in a specific antibody response. The display of the pathogenic isoform was aimed by two different strategies. The first one was directed at the conversion of the proteinase K (PK) sensitive from of PrP on the surface of PrPD-retroparticles into the PK resistant form. Albeit specific adaption of the PK digestion assay detecting resistant PrP, no PrP conversion was observed for PrPD-retroparticles. The second approach utilized a replication competent variant of the ecotropic MLV displaying PrPc on the viral Env protein. This MLV variant was stable in cell culture for six passages but did not replicate on scrapie-infected, PrPSc-propagating neuroblastoma cells. Thus, besides PrPc-displaying virus-like particles a replication competent MLV variant was obtained, which stably incorporated PrPc at the N-terminus of the viral Env protein. The incorporation of the cell-surface located PrPc into particles was expected from previously obtained data on protein display in the context of retrovirus-derived particles. Thus, the lack of incorporation observed for the complete PrPc sequence was rather unexpected and was found to be inhibited at both, fusion to PDGFR and the viral Env. In contrast to N-terminally truncated PrPc, the complete PrPc was shown to exhibit increased cell surface internalization rates and half-life times eventually contributing to the observed results. The PrP-vaccination approach described in this work represents the first successful system inducing PrP-specific antibody responses against the prion protein in wt mice. Explanations at this are based on the induction of specific T cell help or effects of the innate immunity, respectively. MLV-and HIV-derived particles bearing the PrP-coding sequence or being replication competent variants generated during this thesis might help to further improve the PrP-specific immune response.

Durch RNAinterferenz (RNAi) läßt sich die Expression eines beliebigen Gens spezifisch unterdrücken. Dafür müssen in das Zytoplasma kurze, doppelsträngige RNA Moleküle (siRNA bzw. shRNA) eingebracht werden, die teilweise komplementäre Sequenzen zu dem Zielgen aufweisen. Um siRNAs mit einer hohen Effizienz und Kopienzahl in die Zielzelle einzubringen, wurden Transfersysteme unterschiedlicher Art entwickelt. Nicht-virale Transfersysteme können nur einen transienten Effekt auslösen - ein Umstand, der für Langzeitstudien eine mehrfache Transfektion bedingt. Zur Lösung dieses Problems wurden retrovirale Vektorsysteme entwickelt, die durch Integration der shRNA-Expressionskassette in das zelluläre Genom eine stabile Unterdrückung eines Zielgens erreichen können. Insbesondere für präklinische Studien in vivo ist jedoch ein System mit erhöhter Transferrate wünschenswert, um in möglichst vielen Zielzellen einen RNAi-Effekt zu bewirken. Sliva et al. konnten zeigen, dass das Murine Leukämie Virus (MLV) theoretisch diese Anforderung erfüllt. Dafür wurde eine shRNA-Expressionskassette in das Virusgenom eingefügt und in vitro ein RNAi-Effekt nachgewiesen. In der vorliegenden Arbeit wurde dieses System nun durch die Verwendung von microRNA-adaptierten shRNAs (shRNAmir) verbessert. In mehreren Publikationen wurde bestätigt, dass shRNAs, die endogenen microRNAs nachempfunden sind, eine höhere Effizienz und niedrigere Toxizität aufweisen. Zunächst wurde die für die genetische Stabilität optimale Orientierung der shRNAmir-Expressionskassette bestimmt. Das Konstrukt in reverser Orientierung wies eine Deletion in der shRNAmir Promotersequenz auf, die wahrscheinlich durch Interferenz mit dem 5’LTR Promoter entstanden ist. Mit dem genetisch stabilen Viruskonstrukt wurden Experimente zur Reduktion der Expression von Markergenen durchgeführt, um die Effizienz der RNAi-Aktivität leicht zu quantifizieren. Dafür wurden humane Fibrosarkom (HT1080) Zellen infiziert, die eGFP oder Luziferase stabil exprimieren. Mit eGFP- und Luziferase-spezifischen shRNAmir-Expressionskassetten konnte nach Infektion eine Herunterregulation von eGFP auf etwa 20 % und für Luziferase auf unter 10% beobachtet werden. Das Kontrollvirus, das eine unspezifische shRNAmir kodiert, hatte keinen Einfluss auf die Expression beider Markerproteine. Die Kinetik mit der die Markerproteine herrunterreguliert wurden, war abhängig von der Virusdosis. Die Virusdosis hatte aber keinen Einfluß auf die Stärke des RNAi-Effekts, der nach Infektion aller Zellen festgestellt werden konnte. Dieses Ergebnis entspricht der Erwartung an ein replikatives Transfersystems, das je nach applizierter Virusdosis unterschiedlich schnell RNAi in der Zellkultur ausbreitet und induziert. Die Anwendbarkeit dieses RNAi-Transfersystems auch für endogene Gene wurde mit MMP14-spezifischen shRNAmirs gezeigt. Nach Infektion von HT1080 Zellen mit den entsprechenden Viren in HT1080 Zellen konnte eine verringerte Menge an MMP14 mRNA und Protein nachgewiesen werden. Dies konnte funktionell durch eine verringerte Menge an intermediärem MMP2 und durch eine reduzierte Invasivität bestätigt werden. Zudem war die Fähigkeit dieser Zellen subkutane Tumore zu bilden stark eingeschränkt. Um die Anwendbarkeit dieses Systems für in vivo Applikationen zu zeigen, wurde in Mäuse, die Luziferase-exprimierenden Tumoren trugen, MLV-shLuc oder das Kontrollvirus systemisch appliziert. 21 Tage nach Virusgabe konnte in den Tumoren von MLV-shLuc infizierten Mäusen eine Abnahme der Luziferaseaktivität auf 15 % nachgewiesen werden. Auch in Mäusen, die systemisch applizierte Tumorzellen erhielten, konnte eine Tendenz von RNAi-vermittelter Luziferase-Reduktion beobachtet werden. Damit wurde in dieser Arbeit ein neuartiges RNAi-Transfersystem geschaffen, das in der Lage ist, auch in vivo einen starken und lang andauernden RNAi-Effekt auszulösen. Die Einzigartigkeit besteht in der Kombination von shRNAmir und Replikations-kompetenten Retroviren. Dadurch konnte eine erweiterte Transferrate von shRNAmir in Tumorzellen erreicht werden, so dass nun Genfunktionsstudien mit sehr hoher Aussagekraft möglich sind.